Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Neoadjuvant Carboplatin and Paclitaxel for ESCC
NCT04177797Phase 2Unknown
- Sponsor
- Sichuan Cancer Hospital
- Start
- Mar 2020
- Primary completion
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sichuan Cancer Hospital. Status: unknown.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04177797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04177797.